drug development

How Many Drugs in Development Eventually Get Approved? More Than You’d Think
How Many Drugs in Development Eventually Get Approved? More Than You’d Think
Xtalks
drug development
FDA
drug approvals
Flag link:
Is Pharma's Data Problem Technical Or Cultural?
Is Pharma's Data Problem Technical Or Cultural?
Forbes
Big Data
drug development
Flag link:
Novartis ties a new round of biosimilar development programs to a partnership deal with India’s Biocon
Novartis ties a new round of biosimilar development programs to a partnership deal with India’s Biocon
Endpoints
Novartis
Biocon
drug development
biosimilars
Flag link:
Pfizer lines up an $830M alliance with Arvinas on protein degradation
Pfizer lines up an $830M alliance with Arvinas on protein degradation
Endpoints
Pfizer
Arvinas
targeted protein degradation
drug development
Flag link:
Sangamo shares surge 3.4% on $12 mln ALS gene therapy collaboration with Pfizer
Sangamo shares surge 3.4% on $12 mln ALS gene therapy collaboration with Pfizer
Marketwatch
Sangamo
Pfizer
ALS
gene therapy
drug development
Flag link:
Trump v. Drug Makers? And 6 More Burning Biopharma Questions for 2018
Trump v. Drug Makers? And 6 More Burning Biopharma Questions for 2018
Xconomy
Donald Trump
pharma industry
gene therapy
DNA testing
opioid crisis
drug development
digital healthcare
microbiome
Flag link:
Bristol-Myers teams up with Opdivo maker Ono Pharmaceutical on new I/O programs
Bristol-Myers teams up with Opdivo maker Ono Pharmaceutical on new I/O programs
Endpoints
Bristol-Myers Squibb
Opdivo
Ono Pharmaceutical
ONO-4578
immuno-oncology
drug development
Flag link:
Roche study finds cancer 'Velcro' that halts T-cell attack
Roche study finds cancer 'Velcro' that halts T-cell attack
Reuters
Roche
T-cells
cancer
drug development
Flag link:
Have PRVs Incentivized New Rare or Neglected Disease Research? Experts Discuss
Have PRVs Incentivized New Rare or Neglected Disease Research? Experts Discuss
RAPS.org
priority review vouchers
Rare Diseases
R&D
drug development
Flag link:
FDA opens door to multi-arm, multi-company clinical trials
FDA opens door to multi-arm, multi-company clinical trials
Fierce Biotech
FDA
clinical trials
drug development
Flag link:
There are 2,004 cancer immunotherapies crowding into the pipeline. Now what?
There are 2,004 cancer immunotherapies crowding into the pipeline. Now what?
Endpoints
cancer
immuno-oncology
drug development
R&D
Flag link:
More efficient rare pediatric drug development: FDA drafts guidance
More efficient rare pediatric drug development: FDA drafts guidance
Endpoints
FDA
drug development
Rare Diseases
pediatrics
Flag link:
Gloomy results from the research for an Alzheimer’s therapy
Gloomy results from the research for an Alzheimer’s therapy
GoinPharma
Alzheimer's disease
Merck
Eli Lilly
Lundbeck
Biogen
Denali Therapeutics
Yumanity Therapeutics
drug development
Flag link:
This Is Why Blockchains Will Transform Healthcare
This Is Why Blockchains Will Transform Healthcare
Forbes
blockchain
medical data
drug development
Flag link:
Merck blueprints $1.3B research hub in a post-Brexit London, with 950 staffers
Merck blueprints $1.3B research hub in a post-Brexit London, with 950 staffers
Endpoints
Merck
London
R&D
drug development
Brexit
Flag link:
In the search for Alzheimer’s drugs, researchers must look beyond beta amyloid
In the search for Alzheimer’s drugs, researchers must look beyond beta amyloid
Stat
R&D
drug development
Alzheimer's disease
beta amyloid
Bill Gates
Flag link:
Merck strikes autoimmune deal with newly-emerged Cue
Merck strikes autoimmune deal with newly-emerged Cue
BioPharma Dive
Merck
autoimmune disease
Cue Biopharma
R&D
drug development
Flag link:
J&J antes $50M to get Zymeworks’ 6th big bispecifics alliance underway, with $6B in total milestones on the table
J&J antes $50M to get Zymeworks’ 6th big bispecifics alliance underway, with $6B in total milestones on the table
Endpoints
JNJ
Zymeworks
drug development
bispecific antibodies
Flag link:
An explosion of PD-1/L1 checkpoint studies is crowding the industry pipeline — and that’s a problem
An explosion of PD-1/L1 checkpoint studies is crowding the industry pipeline — and that’s a problem
Endpoints
anti-PD-L1
drug development
Flag link:
GSK R&D chief Vallance is out as its new CEO changes direction under a new crew
GSK R&D chief Vallance is out as its new CEO changes direction under a new crew
Endpoints
GSK
R&D
restructuring
drug development
Flag link:

Pages